Clinical Research Malaysia (CRM) collaborates with IQVIA
Clinical Research Malaysia (CRM) recently signed a memorandum of understanding (MoU) to establish a strategic alliance with IQVIA’s global Early Phase Oncology Network (EPON).
The agreement makes Clinical Research Centre at Sarawak General Hospital the first in Southeast Asia to be part of IQVIA’s prestigious network of globally qualified Phase I oncology sites. CRM, established by the Ministry of Health in 2012, exists to advance Malaysia’s ability to contribute to global health solutions. IQVIA is a leading global provider of contract research services, advanced analytics and technology solutions to the life-sciences industry.
Iron deficiency is a health-related condition
Compai Pharma and Pharmacosmos recently announced their partnership to launch MonoFer, an innovative parenteral iron formulation for the treatment of iron deficiency by the end of 2018.
Compai Pharma has been granted exclusive rights to market, distribute and sell iron isomaltoside in Malaysia, and will promote the brand through its own medical and sales team across the country. Iron deficiency is a health-related condition in which iron availability is insufficient to meet the body’s needs and negatively impacting one’s quality of life. It can be present with or without anaemia.
Merck in agreement with Cyclica for aI-augmented screening platform
Merck, a leading science and technology company, today announced that it has entered into a licensing agreement with Cyclica Inc. for the use of Ligand Express®, a cloud-based in silico proteome screening platform. Ligand Express® is a structure-based and artificial intelligence (AI) augmented proteome screening platform that is being used to uncover novel targets that are modelled to interact with a small molecule.
This year-long agreement will enable Merck to quickly and efficiently elucidate mechanisms of action, evaluate safety profiles and explore additional applications for a number of its investigational small molecules, including those identified in highly disease-relevant phenotypic screens.
Henry Schein and Vets First Choice announce new name of the planned new company: Covetrus
Henry Schein, Inc. (Nasdaq: HSIC) and Vets First Choice today announced that the new standalone public company that will result from the planned spin-off of the Henry Schein Animal Health business and the subsequent merger with Vets First Choice will be named Covetrus.The transaction is expected to be completed in the first quarter of 2019.
The new company, Covetrus, will be a global, technology-enabled animal health business supporting the companion, equine and large-animal veterinary markets.